OBJECTIVE: To determine whether clinicians discuss bone-specific side-effects with patients on androgen-deprivation therapy (ADT) for prostate cancer, or prescribe lifestyle and pharmacological interventions for low bone mineral density (BMD), as decreased BMD is a common side-effect of ADT, leading to increased risk of fracture. PATIENTS AND METHODS: Sixty-six men (mean age 70.6 years) with non-metastatic prostate cancer and starting continuous ADT were enrolled in a prospective longitudinal study. BMD was determined by dual X-ray absorptiometry (DXA) at baseline. Patients were interviewed to obtain their medical histories, and charts were reviewed to determine whether clinicians documented potential bone side-effects in clinic notes, and made lifestyle and/or medication recommendations. Both were done at the start of ADT, and 3 and 6 months later. Patients were classified based on DXA T-score as having normal BMD, as osteopenic, or osteoporotic. RESULTS: At baseline, 53% of patients had osteopenia and 5% had osteoporosis. Within 6 months of starting ADT, general side-effects and bone-specific side-effects of ADT were documented as being discussed with 26% and 15%, respectively. Clinicians recommended lifestyle interventions to 11% of patients. Pharmacological interventions (calcium, vitamin D, and/or bisphosphonates) were recommended to 18% of all patients within 6 months of starting ADT, and to 26% and 67% of osteopenic and osteoporotic patients, respectively. CONCLUSIONS: A minority of patients is being informed of bone-specific side-effects of ADT. Lifestyle and drug interventions to prevent declines in BMD were recommended uncommonly. Practices around bone health for men starting ADT are suboptimal.
OBJECTIVE: To determine whether clinicians discuss bone-specific side-effects with patients on androgen-deprivation therapy (ADT) for prostate cancer, or prescribe lifestyle and pharmacological interventions for low bone mineral density (BMD), as decreased BMD is a common side-effect of ADT, leading to increased risk of fracture. PATIENTS AND METHODS: Sixty-six men (mean age 70.6 years) with non-metastatic prostate cancer and starting continuous ADT were enrolled in a prospective longitudinal study. BMD was determined by dual X-ray absorptiometry (DXA) at baseline. Patients were interviewed to obtain their medical histories, and charts were reviewed to determine whether clinicians documented potential bone side-effects in clinic notes, and made lifestyle and/or medication recommendations. Both were done at the start of ADT, and 3 and 6 months later. Patients were classified based on DXA T-score as having normal BMD, as osteopenic, or osteoporotic. RESULTS: At baseline, 53% of patients had osteopenia and 5% had osteoporosis. Within 6 months of starting ADT, general side-effects and bone-specific side-effects of ADT were documented as being discussed with 26% and 15%, respectively. Clinicians recommended lifestyle interventions to 11% of patients. Pharmacological interventions (calcium, vitamin D, and/or bisphosphonates) were recommended to 18% of all patients within 6 months of starting ADT, and to 26% and 67% of osteopenic and osteoporoticpatients, respectively. CONCLUSIONS: A minority of patients is being informed of bone-specific side-effects of ADT. Lifestyle and drug interventions to prevent declines in BMD were recommended uncommonly. Practices around bone health for men starting ADT are suboptimal.
Authors: Susan L Greenspan; Penelope Coates; Susan M Sereika; Joel B Nelson; Donald L Trump; Neil M Resnick Journal: J Clin Endocrinol Metab Date: 2005-09-27 Impact factor: 5.958
Authors: M R Smith; F J McGovern; A L Zietman; M A Fallon; D L Hayden; D A Schoenfeld; P W Kantoff; J S Finkelstein Journal: N Engl J Med Date: 2001-09-27 Impact factor: 91.245
Authors: Matthew R Smith; Simone Peart Boyce; Erick Moyneur; Mei Sheng Duh; Monika K Raut; Jane Brandman Journal: J Urol Date: 2006-01 Impact factor: 7.450
Authors: Shabbir M H Alibhai; Sameera Rahman; Padraig R Warde; Michael A S Jewett; Taha Jaffer; Angela M Cheung Journal: Urology Date: 2006-07 Impact factor: 2.649
Authors: John B Malcolm; Ithaar H Derweesh; Matthew C Kincade; Christopher J DiBlasio; Kimberly D Lamar; Robert W Wake; Anthony L Patterson Journal: Can J Urol Date: 2007-06 Impact factor: 1.344
Authors: Terrence H Diamond; Celestia S Higano; Matthew R Smith; Theresa A Guise; Frederick R Singer Journal: Cancer Date: 2004-03-01 Impact factor: 6.860
Authors: Annie-Claude M Lassemillante; Suhail A R Doi; John D Hooper; John B Prins; Olivia R L Wright Journal: Endocrine Date: 2015-01-31 Impact factor: 3.633
Authors: Joshua M Lang; Marianne Wallace; Jordan T Becker; Jens C Eickhoff; Bjoern Buehring; Neil Binkley; Mary Jane Staab; George Wilding; Glenn Liu; Miroslav Malkovsky; Douglas G McNeel Journal: Clin Genitourin Cancer Date: 2013-07-05 Impact factor: 2.872
Authors: Derek S Tsang; Jennifer M Jones; Osai Samadi; Suhayb Shah; Nicholas Mitsakakis; Charles N Catton; William Jeon; Joshua To; Henriette Breunis; Shabbir M H Alibhai Journal: Support Care Cancer Date: 2018-03-12 Impact factor: 3.603
Authors: Ary Serpa Neto; Marcos Tobias-Machado; Marcos A P Esteves; Marília D Senra; Marcelo L Wroclawski; Fernando L A Fonseca; Rodolfo B dos Reis; Antônio C L Pompeo; Auro Del Giglio Journal: BMC Urol Date: 2010-05-19 Impact factor: 2.264
Authors: Tisheeka R Graham-Steed; Pamela R Soulos; Natalie Dearing; John Concato; Mary E Tinetti; Cary P Gross Journal: J Geriatr Oncol Date: 2014-09-18 Impact factor: 3.599